



Guide to
INTRODUCING
HPV VACCINE
INTO NATIONAL
IMMUNIZATION
PROGRAMMES

The Department of Immunization, Vaccines and Biologicals thanks the donors whose unspecified financial support has made the production of this document possible.

This document was published by the Expanded Programme on Immunization (EPI) of the Department of Immunization, Vaccines and Biologicals

Printed: December 2016

This publication is available on the Internet at: www.who.int/immunization/documents

Copies of this document as well as additional materials on immunization, vaccines and biologicals may be requested from:

World Health Organization
Department of Immunization, Vaccines and Biologicals
CH-1211 Geneva 27
Switzerland
Fax: + 41 22 791 4227
Email: vaccines@who.int

WHO Library Cataloguing-in-Publication Data

Guide to Introducing HPV Vaccine into National Immunization Programmes

1. Papillomavirus Vaccines. 2. Uterine Cervical Neoplasms – prevention and control. 3. Immunization Programs. I. World Health Organization.

ISBN 978 92 4 154976 9

(NLM classification: WP 480)

© World Health Organization 2016

All rights reserved. Publications of the World Health Organization are available on the WHO website (<http://www.who.int>) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website (http://www.who.int/about/licensing/copyright_form/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Design and layout: Paprika (Annecy, France)

Printed by the WHO Document Production Services, Geneva, Switzerland

Photo credits: Cover: © UNICEF/UNI89039/Purushotham

Guide to

INTRODUCING

HPV VACCINE

INTO NATIONAL
IMMUNIZATION
PROGRAMMES

TABLE OF CONTENTS

Abbreviations	VII
About this guide	IX
1. INTRODUCTION	X
HPV infection and cervical cancer	1
HPV vaccination: Part of a comprehensive approach to prevention of cervical cancer	2
HPV vaccines	4
HPV vaccination: Something new and different for immunization programmes	6
WHO Recommendations for HPV Vaccination	9
2. DECISION-MAKING AT COUNTRY LEVEL	12
What should be the process?	13
What information is needed?	14
Will HPV vaccination be financially sustainable?	15
What delivery strategy for HPV vaccination is best?	17
How can HPV vaccine be integrated with other vaccinations or health interventions?	23
What policies need to be in place?	26
Who are key stakeholders to include in the process?	27
3. PLANNING	28
What plans need to be made or revised?	29
How to plan for national introduction?	29
How to select the target population for HPV vaccination?	30
How can the number of girls to be vaccinated with HPV vaccine be estimated?	32
Where can you find the girls targeted for HPV vaccination?	33
How much will it cost to introduce HPV vaccine?	33
How to coordinate with other stakeholders?	34
4. VACCINE MANAGEMENT	36
How to forecast and calculate vaccine supply needed for HPV vaccine?	37
What cold chain capacity will be required for HPV vaccine?	37
How should HPV vaccines be stored and handled?	38
5. MICROPLANNING AT THE DISTRICT LEVEL	42
Verifying the estimated target population	43
Ensuring that cold chain capacity is adequate	43
Planning and coordinating logistics for vaccine delivery at outreach locations in schools and communities	44
Consent for vaccination	45
6. COMMUNICATION AND SOCIAL MOBILIZATION	46
Developing a Communication Plan	47
Developing key messages for HPV vaccines	48
Identifying the audiences	48
Using multiple channels and opportunities for communication	49
Rumours and crisis management	51
7. IMPLEMENTATION – TRAINING, SERVICE DELIVERY AND SUPERVISION	54
Training	55
Service delivery	56
Supportive supervision	61

8. MONITORING AND EVALUATION	62
Monitoring tools	63
Evaluation tools	67
ANNEXES	70
Annex 1. UN Population Division – Female population by single age, major area, region and country, annual estimates 1950-2100	71
Annex 2. How to perform a shake test	73
Annex 3. Timing and frequency for HPV vaccine communications – a country example	74
Annex 4. Observed rate of vaccine reactions – HPV vaccine	75
Annex 5. Sample AEFI reporting form	79
Annex 6. Aid memoire for AEFI Investigation and Sample AEFI Investigation Form	81
Annex 7. Sample HPV vaccine register (integrated with other vaccines)	85
Annex 8. Sample tally sheet	86
Annex 9. Sample vaccination card	87
Annex 10. Sample monthly vaccination report	88
Annex 11. Frequently Asked Questions (FAQs)	89

ABBREVIATIONS

AD syringe	Auto-disable syringe
AEFI	Adverse event following immunization
cMYP	Comprehensive multi-year plan
CTC	Controlled Temperature Chain
EPI	Expanded Programme on Immunization
EVM	Effective vaccine management
GACVS	Global Advisory Committee on Vaccine Safety
HIV	Human immunodeficiency virus
HPV	Human papillomavirus
IARC	International Agency for Research on Cancer
ICC	Inter-agency coordinating committee
IEC	Information, education and communication
MOH	Ministry of Health
NITAG	National immunization technical advisory group
SAGE	Strategic advisory group of experts on immunization
UNESCO	United Nations Education, Scientific and Cultural Organization
UNFPA	United Nations Population Fund
UNICEF	United Nations Children's Fund
VLP	Virus-like particle
VVM	Vaccine vial monitor
WHO	World Health Organization

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_26740

